surmount-1 tirzepatide weight loss percent 72 weeks Adults with obesity using maintain 'remarkable' at 88 Oral tirzepatide: what actually exists,

Abdominal obesity also reduces lung volumes, making respiratory efforts less effective at keeping the airway open

Side Effects and Safety Profile Common Side Effects Gastrointestinal effects are the most frequently reported adverse events in clinical trials: Nausea (reported by 1233% of participants depending on dose) Diarrhea (1223%) Constipation (611%) Vomiting (59%) Decreased appetite (considered both a therapeutic effect and side effect) Abdominal pain (58%) Dyspepsia/heartburn (58%) These effects are most common during dose escalation and typically improve within 24 weeks at each new dose level

However, its important to note the limitations of research

Will insurance cover GLP-1 Microdosing

Adults struggling with obesity or related conditions such as type 2 diabetes, high blood pressure, or high cholesterol may find tirzepatide particularly beneficial